In a phase 2b trial of 344 patients in Japan with dry eye disease, SJP-0132 eye drops (0.1%, 0.3% or 1.0%) did not significantly improve corneal fluorescein staining at 4 weeks vs placebo (0.3%: difference −0.8; P=.1181); some secondary endpoints improved.
RCTn = 344
Hori et al. Efficacy and Safety of SJP-0132 in Patients With Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study